Drug Trial Radar · NCT06333483
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
Feb 2, 2024
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Autolus LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
Obecabtagene autoleucel (obe-cel)Biological
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicitiesTime frame: Up to 28 days from obe-cel infusion
- Adverse eventsTime frame: Up to Month 12
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Hospital Universitari Vall Hebrón
Barcelona, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Addenbrookes Hospital
Cambridge, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Manchester Royal Infirmary, Manchester University NHS Foundation Trust,
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.